Skip to main content
. 2014 Dec 15;5(1):72–82.

Figure 1.

Figure 1

Change in PSA (A), 18F-NaF-PET/CT (B) and 18F-FDG-PET/CT (C) at baseline and 8 week follow-up in a man with mCRPC and widespread 18F-NaF-avid and 18F-FDG-avid disease who remained on trial for 53 days; Change in PSA (D), 18F-NaF-PET/CT (E) and 18F-FDG- PET/CT (F) at baseline and 8 week follow-up in a man with mCRPC, widespread 18F-NaF-avid and non-18F-FDG-avid disease who remained on trial for 225 days.